Fig. 2

Prothrombin time changes from baseline for all ages and all doses with (a) rivaroxaban tablet and (b) rivaroxaban suspension. Light grey dots are data points from healthy adult volunteers; coloured dots represent individual data from children. A linear relationship was assumed for the concentration–response curve. 99% prediction intervals were used to depict the variability in the pooled data. The two reference populations consisted of healthy adult volunteers from phase I trials, who received either a single dose of rivaroxaban 10 mg (age 18–40 years, n = 171), or a single dose of rivaroxaban 20 mg (age 18–40 years, n = 101). PT change from baseline (x-fold) is individual PT at a distinct time point, divided by individual PT prior to drug administration. eq., equivalent; PT, prothrombin time